Cardiol Therapeutics (CRDL) Debt to Equity (2021 - 2026)

Cardiol Therapeutics has reported Debt to Equity for 6 years, with the latest figure at $0.15 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to $0.15; the trailing twelve-month figure through Mar 2026 stood at $0.15 (changed N/A YoY), and the FY2025 full-year result was $0.12, changed N/A from the prior year.
• Debt to Equity for Q1 2026 stood at $0.15, up from $0.12 in the prior quarter.
• The five-year high for Debt to Equity was $0.15 in Q1 2026, with the low at $0.0 in Q3 2024.
• Historically, Debt to Equity has averaged $0.05 across 5 years, with a median of $0.03 in 2022.
• The largest YoY upside for Debt to Equity was 1244.15% in 2024 against a maximum downside of 98.49% in 2024.
• Cardiol Therapeutics' Debt to Equity stood at $0.01 in 2022, then increased by 4.83% to $0.01 in 2023, then plunged by 95.85% to $0.0 in 2024, then soared by 34103.8% to $0.12 in 2025, then advanced by 26.71% to $0.15 in 2026.
• The last three Debt to Equity figures came in at $0.15 (Q1 2026), $0.12 (Q4 2025), and $0.0 (Q3 2024), per Business Quant data.